D. Boral Capital Has Lowered Expectations for Quince Therapeutics (NASDAQ:QNCX) Stock Price

Quince Therapeutics (NASDAQ:QNCX - Free Report) had its price objective reduced by D. Boral Capital from $12.00 to $4.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Oppenheimer began coverage on shares of Quince Therapeutics in a research report on Monday, March 24th. They set an "outperform" rating and a $10.00 price target for the company. Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a "buy" rating and a $9.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Quince Therapeutics currently has a consensus rating of "Buy" and an average price target of $8.00.

Quince Therapeutics Stock Performance

Shares of NASDAQ:QNCX traded down $0.05 during trading on Tuesday, hitting $1.35. 47,716 shares of the stock traded hands, compared to its average volume of 244,789. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $1.45. The company has a market cap of $59.40 million, a price-to-earnings ratio of -1.09 and a beta of 0.71.

Remove Ads

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The firm had revenue of $0.17 million during the quarter. As a group, equities analysts predict that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Quince Therapeutics

Institutional investors have recently bought and sold shares of the stock. Anfield Capital Management LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter worth $50,000. Virtu Financial LLC acquired a new position in shares of Quince Therapeutics in the 4th quarter valued at approximately $55,000. Two Sigma Investments LP bought a new position in Quince Therapeutics during the 4th quarter valued at $57,000. Northern Trust Corp lifted its position in shares of Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after purchasing an additional 16,501 shares during the last quarter. Finally, Scharf Investments LLC acquired a new position in shares of Quince Therapeutics in the 4th quarter worth approximately $170,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.